TIMI

The 'Thrombolysis In Myocardial Infarction', or TIMI Study Group is an Academic Research Organization (ARO) affiliated with Brigham and Women's Hospital and Harvard Medical School. The group has its headquarters in Boston, Massachusetts, and a satellite location in Quincy. The 'Thrombolysis In Myocardial Infarction', or TIMI Study Group is an Academic Research Organization (ARO) affiliated with Brigham and Women's Hospital and Harvard Medical School. The group has its headquarters in Boston, Massachusetts, and a satellite location in Quincy. The TIMI Study Group was founded by Eugene Braunwald, MD in 1984. Dr. Braunwald held the chairmanship until 2010, when he appointed Marc Sabatine, MD to the position. The group has conducted numerous practice-changing clinical trials in patients with cardiovascular disease or risk factors for cardiovascular disease. Among the group's most important contributions to medicine is the TIMI Risk Score, which assess the risk of death and ischemic events in patients experiencing unstable angina (UA) or a non-ST elevation myocardial infarction (NSTEMI). In patients with UA/NSTEMI, the TIMI risk score is a simple prognostication scheme that categorizes a patient's risk of death and ischemic events and provides a basis for therapeutic decision making. TIMI Score Calculation (1 point for each): Score Interpretation: % risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization. 'TIMI risk' estimates mortality following acute coronary syndromes. TIMI risk can be calculated on the TIMI website under 'Clinical Calculators.' The TIMI Risk Score for STEMI is also useful for patients with known STEMI. Though these patients have a clear protocol - normally thrombolysis or Percutaneous coronary intervention - and are already high risk for mortality, the TIMI Risk Score for STEMI provide risk stratification which helps treatment decisions after acute issues have been resolved. 'TIMI Grade Flow' is a scoring system from 0-3 referring to levels of coronary blood flow assessed during percutaneous coronary angioplasty: